Market Cap (In GBp)
201.45 Million
Revenue (In GBp)
41.28 Million
Net Income (In GBp)
-37.92 Million
Avg. Volume
36.81 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 259.14-430.0
- PE
- -6.33
- EPS
- -0.3
- Beta Value
- 1.16
- ISIN
- US57777K1060
- CUSIP
- 57777K106
- CIK
- -
- Shares
- 106027730.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Mr. Maher Masoud
- Employee Count
- -
- Website
- https://maxcyte.com
- Ipo Date
- 2016-03-29
- Details
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
More Stocks
-
2327
-
BCABBioAtla, Inc.
BCAB
-
ORS
-
AAFRFAirtel Africa Plc
AAFRF
-
PATANJALIPatanjali Foods Limited
PATANJALI
-
GPSO
-
AGROPHOSAgro Phos (India) Limited
AGROPHOS
-
RCK